No Data
No Data
Stifel Maintains Zymeworks(ZYME.US) With Buy Rating, Maintains Target Price $21
Stifel analyst Stephen Willey maintains $Zymeworks(ZYME.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate of 41.4% and a total
Stifel Nicolaus Keeps Their Buy Rating on Zymeworks (ZYME)
Zymeworks Appoints New EVP and CFO; Leadership Transition
Express News | Zymeworks - on August 30, Kenneth Galbraith Resigned From Positions of Interim CFO and as Principal Financial Officer and Principal Accounting Officer
Zymeworks Engages Investors, Awaits Drug Approval
Zymeworks Announces Participation in Upcoming Investor Conferences